Conclusion
This meta-analysis demonstrated the efficacy of HER2-targeted ADCs in GC and GEJC patients as second- and later-line treatments. Patients with HER2 overexpression benefitted more from these novel drugs than patients with low HER2 expression. Regarding safety, the high incidence of grade3 and above AEs is worthy of attention. However, given the currently limited clinical data, further validation is needed in larger-scale RCTs in the future.